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Doxorubicin induces caspase-mediated proteolysis
of KV7.1
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Kv7.1 (KCNQ1) coassembles with KCNE1 to generate the cardiac IKs-channel. Gain- and loss-
of-function mutations in KCNQ1 are associated with cardiac arrhthymias, highlighting the
importance of modulating IKs activity for cardiac function. Here, we report proteolysis of Kv7.1
as an irreversible posttranslational modiﬁcation. The identiﬁcation of two C-terminal frag-
ments of Kv7.1 led us to identify an aspartate critical for the generation of one of the
fragments and caspases as responsible for mediating proteolysis. Activating caspases
reduces Kv7.1/KCNE1 currents, which is abrogated in cells expressing caspase-resistant
channels. Enhanced cleavage of Kv7.1 can be detected for the LQT mutation G460S, which is
located adjacent to the cleavage site, whereas a calmodulin-binding-deﬁcient mutation
impairs cleavage. Application of apoptotic stimuli or doxorubicin-induced cardiotoxicity
provokes caspase-mediated cleavage of endogenous IKs in human cardiomyocytes. In sum-
mary, caspases are novel regulatory components of IKs channels that may have important
implications for the molecular mechanism of doxorubicin-induced cardiotoxicity.
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Voltage-gated potassium channels (Kv) form a protein classcomprising 40 members in humans, which can begrouped into 12 families1. Among these, the Kv7 (KCNQ)
family has attracted special attention since mutations in the ﬁve
KCNQ genes cause heritable diseases, highlighting their physio-
logical importance2,3. Dominant-negative mutations in the gene
encoding Kv7.1 are associated with cardiac arrhythmias con-
tributing to LQT syndrome4, whereas patients carrying loss-of-
function mutations on both alleles additionally suffer from severe
congenital hearing loss5. Gain-of-function mutations were found
in patients with a form of autosomal dominant atrial ﬁbrillation6,
highlighting the important functions of Kv7.1 in the heart and
inner ear. In both tissues, the α-subunit Kv7.1 coassembles with
the β-subunit KCNE1, composing an ion channel conducting the
slow component of the delayed rectiﬁer potassium current, IKs,
which is indispensable for shaping the cardiac action potential7,8.
Another important physiological function of Kv7.1 was dis-
covered by genome-wide association studies, in which single
nucleotide polymorphisms in the KCNQ1 locus were associated
with type 2 diabetes in several populations9,10. In nonexcitable
(e.g., polarized thyroid, intestinal and tracheal epithelial) cells,
Kv7.1 associates with the β-subunits KCNE2 and KCNE3,
respectively. The latter β-subunits, in contrast to KCNE1, reduce
the voltage-dependent gating of the outwardly rectifying Kv7.1
α-subunit, resulting in constitutively open channels. The Kv7.1/
KCNE2 channel complex has been described to be crucial for
thyroid hormone biosynthesis11, whereas Kv7.1/KCNE3 hetero-
dimers play an important role in chloride secretion across tra-
cheal and intestinal epithelia12. In the intestine, transposon-based
forward mutagenesis genetic screens identiﬁed KCNQ1 as a
cancer susceptibility gene13 and low expression of Kv7.1 was
found in patients with colorectal cancer14. However, the role of
Kv7.1 in cancer development has yet to be established.
Channels formed from Kv7 α-subunits share some structural
features with Shaker-related Kv channels, such as a common core
structure of six transmembrane domains (S1−S6) including a
voltage-sensing domain (S1−S4) and a pore domain (S5−S6)2.
One striking difference, however, is the presence of a large
cytoplasmic C-terminal domain in Kv7 channels, which is
important for gating, assembly, and intracellular trafﬁcking of the
channel and comprises four helical domains (A−D) (reviewed in
Haitin and Attali15). Whereas helices A and B mediate calmo-
dulin binding16, helices C and D form the subunit interaction
domain17, which consists of a bipartite coiled-coil motif that is
crucial for subunit-speciﬁc interaction and tetramerization of the
Kv7 α-subunits18,19. For Kv7.1, it has also been shown that
the A-kinase anchoring protein yotiao binds to helix D, leading to
the recruitment of protein kinase A (PKA) and protein phos-
phatase 1, thereby forming a macromolecular complex important
for regulating IKs activity20. In addition to PKA-mediated phos-
phorylation, ubiquitination and sumoylation have been reported
to be important for regulation of Kv7.1 activity at the post-
translational level21,22.
Anthracyclines such as doxorubicin are well-established and
effective antineoplastic agents, commonly used for the treatment
of cancers. However, doxorubicin treatment has cardiotoxicity as
a severe side effect, which can lead to QT prolongation and heart
failure23,24. Increased production of reactive oxygen species
(ROS) and the induction of mitochondrial dysfunction are well-
described molecular mechanisms of doxorubicin-induced cardi-
omyopathy, resulting in an activation of apoptotic pathways,
ﬁnally leading to caspase activation25. Dexrazoxane, a cardio-
protective agent, acts in the same pathway by chelating Fe2+ ions
more effectively than doxorubicin. While Fe2+ ions bound to
doxorubicin are efﬁciently oxidized to Fe3+, resulting in release of
electrons, which are rapidly transferred to produce ROS, the
redox activity of dexrazoxane on Fe2+ ions is much lower, so that
the Fe2+-scavenging activity and the consequently reduced ROS
production by dexrazoxane have been suggested to underlie the
alleviating effect on cardiotoxicity26.
Caspases are cysteine proteases, which speciﬁcally cleave their
substrates at the C-terminal side of an aspartic acid and play
important roles in numerous aspects of physiology such as
apoptosis, aging, development, and inﬂammation27. Caspases are
well known for their executive role in apoptosis and can be
grouped into initiator (caspase 2, 8–10) and effector caspases
(caspase 3, 6 and 7)28. Activation of caspases is triggered either by
the extrinsic pathway, mediated by ligand binding to death
receptors and activation of the initiator caspase 8, or by the
intrinsic pathway28. In the latter case, mitochondrial membranes
are permeabilized by the proapoptotic proteins BCL-2 and BAX,
leading to a loss of mitochondrial transmembrane potentials and
to the release of other proapoptotic proteins such as cytochrome C
into the cytosol, which results in the activation of the initiator
caspase 9. Activated caspases 8 and 9 speciﬁcally cleave effector
caspases, which ﬁnally execute apoptosis28. With the exception of
caspase 14, all other caspases in humans have been implicated in
inﬂammation28. Moreover, altered caspase expression levels have
been correlated with ageing29 and heart failure30,31. Recently, it has
become evident that caspases also have nonapoptotic and nonin-
ﬂammatory functions, such as regulation of long-term depres-
sion32 or organelle removal during terminal differentiation33.
By using Kv7.1-speciﬁc antibodies directed against an epitope
on the channel’s C-terminus, we detected two c-terminal frag-
ments, leading us to the hypothesis that Kv7.1 is processed by
unknown proteases. In the present study, we identify Kv7.1 as a
novel substrate for caspases, which may have important impli-
cations for understanding the role of Kv7.1 in cardiac arrhyth-
mias and its function as a tumor suppressor. Our data suggest
that caspase-mediated proteolysis of Kv7.1 leads to decreased
Kv7.1-mediated currents, representing a novel regulatory
mechanism for modulating Kv7.1 channel activity. Furthermore,
we show that Kv7.1 cleavage is induced upon administration of
doxorubicin, which efﬁciently activates caspase 3 in human
cardiomyocytes. To our knowledge, Kv7.1 is the ﬁrst example of a
voltage-gated potassium channel that acts as a substrate for
caspases.
Results
Proteolysis of Kv7.1 produces C-terminal fragments. We and
others34,35 have noted the occurrence of Kv7.1 C-terminal frag-
ments in transfected cells, when antibodies directed against epi-
topes on the Kv7.1 C-terminus were used, which prompted us to
further analyze the speciﬁcity of these fragments. We found
C-terminal fragments of the full-length Kv7.1 channel in lysates
derived from transiently transfected cells with human or murine
Kv7.1 cDNA constructs (Fig. 1a). Two fragments with a molecular
mass of about ~40 and ~28 kDa can be detected in addition to the
full-length form of Kv7.1 at ~70 kDa, when an antibody directed
against a C-terminally derived peptide of Kv7.1 was used (Fig. 1a
and Supplementary Fig. 1A). Next, we demonstrated the speci-
ﬁcity of the Kv7.1 antibody by the absence of signals in various
tissues derived from Kv7.1-deﬁcient mice, which do not show
detectable Kv7.1 in immunoblots (Supplementary Fig. 1B). As
expected, we found the highest expression of Kv7.1 in murine
heart, when compared to kidney and pancreas, further supporting
the speciﬁcity of the antibody (Supplementary Fig. 1B).
C-terminal fragments of Kv7.1 were also detectable in cells
transfected with a cDNA construct of human Kv7.1 tagged at the
C-terminus with an MYC epitope (Fig. 1b). Immunoblots with
either the MYC or the Kv7.1 antibodies resulted in the same
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pattern. Next, we analyzed neonatal rat ventricular cardiomyo-
cytes (NRVMs) for endogenous expression of Kv7.1. Again, we
found immunoreactive bands resembling full-length Kv7.1 (~70
kDa) and bands at ~40 and ~28 kDa, albeit with low intensity
(Supplementary Fig. 1C). We concluded that Kv7.1 is cleaved
twice at its C-terminus, resulting in three fragments: The N-
terminal fragment comprising the cytoplasmic N-terminus and
the membrane-embedded part of the protein and two C-terminal
fragments showing immunoreactivity with the Kv7.1 antibody,
which we termed CTF1 (~40 kDa) and CTF2 (~28 kDa) (Sup-
plementary Fig. 1A).
To determine the cleavage sites, we generated two Kv7.1
constructs: one comprising the complete C-terminus (CT,
starting with glycine at position 348), and the other beginning
at helix B (CT1 beginning with amino acid 505) (Supplementary
Fig. 1A). After expression of these fragments in HeLa cells, we
compared the size of the resulting bands of CT and CT1 with the
C-terminal fragments CTF1 and CTF2 (Fig. 1c). CT and CTF1
migrate at the same molecular weight, whereas CTF2 runs slightly
slower than the CT1 construct. From these data, we conclude that
the cleavage site for the generation of CTF1 resides between the
end of the transmembrane domain S6 and helix A, while the
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Fig. 1 Kv7.1 is cleaved at aspartate 459. a Western blot analysis of HeLa cell lysates overexpressing human and murine Kv7.1 constructs. Untransfected
cells (Ø) served as negative control. Densitometric analysis of four independent experiments of the CTF1 or CTF2 band intensity normalized to the full-
length Kv7.1 band intensity. b Immunoblot analysis of lysates derived from HeLa cells overexpressing indicated constructs. Untransfected cells (Ø) served
as negative control. c Schematic illustration of different deletion constructs in the linker region between helices A and B. HeLa cell lysates overexpressing
indicated constructs analyzed by western blot. Untransfected cells (Ø) served as negative control. d Alanine scan of position 457 to 462. Lysates from
HeLa cells overexpressing indicated constructs were used for western blot analysis. Untransfected cells (Ø) served as negative control. Densitometric
analysis of six independent experiments of CTF2 band intensity normalized to Kv7.1 full-length band intensity. Statistics were tested with one-way-ANOVA
followed by Bonferroni’s Multiple Comparison test. e Cleavage site sequence logo of Kv7.1 derived from 32 different species. Logo was created with
weblogo.berkley.edu and adapted accordingly. The arrow indicates the cleavage site. a Anti-Kv7.1 antibody. b−d Anti-MYC antibody. All dot blots are
shown as mean and error bars as SEM
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cleavage site for CTF2 likely lies within the loop region between
helices A and B in the C-terminus of Kv7.1.
Since CTF2 is the most abundant C-terminal fragment (Fig. 1a,
b, Supplementary Fig. 1C), we focused our analysis on the region
between helices A and B. We generated ﬁve Kv7.1 constructs with
varying deletions within this linker region (Fig. 1c). Immunoblot
analysis of lysates derived from cells expressing these constructs
revealed that a stretch of six amino acids (S457VDGYD462) was
essential for the occurrence of CTF2 (Fig. 1c). Next, we
performed an alanine scan over the SVDGYD region to deﬁne
the precise cleavage site. Mutating the aspartate at position 459 to
an alanine resulted in a complete loss of CTF2 generation,
whereas mutating the other ﬁve residues (including Asp-462)
appeared to have no signiﬁcant effect (Fig. 1d). These data
demonstrate that Kv7.1 is cleaved within the SVDGYD motif at
position D459 by a protease, which requires an aspartate.
However, Kv7.1 is the only member within the Kv7 family
carrying an aspartate at this position (Supplementary Fig. 1D).
This aspartate is highly conserved within Kv7.1 protein sequences
derived from over 20 different species (Fig. 1e and Supplementary
Fig. 2).
Kv7.1 is cleaved by caspases upon apoptosis. To identify the
protease responsible for the generation of CTF2, we searched
the Merops Database for proteases that require an aspartate in the
cleavage site36. Since caspases critically depend on an aspartate at
the P1 position27, we used two caspase inhibitors (Q-VD-OPH
and Z-VAD(OMe)-FMK) to determine whether caspases are
responsible for the generation of CTF2. Both compounds effec-
tively inhibited the generation of CTF2 but not CTF1 (Fig. 2a and
Supplementary Fig. 3). To activate caspases, we induced apoptosis
in cells overexpressing wild-type Kv7.1 and the D459A mutant by
applying staurosporine, a nonselective protein kinase inhibitor
widely used as a proapoptotic stimulus. Whereas wild-type Kv7.1
was efﬁciently proteolysed, the D459A mutant appeared resistant
to staurosporine treatment (Fig. 2b), demonstrating that the
D459A mutant is insensitive to staurosporine-induced caspase
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Fig. 2 Cleavage of Kv7.1 occurs during apoptosis. a Western blot analysis of Cos7 cells overexpressing Kv7.1-MYC treated for 12 h with 450 nmol per
L Q-VD-OPh. Untransfected (Ø), nontreated and vehicle-treated cells served as negative controls. Densitometric analysis of ﬁve independent experiments
of CTF2 band intensity normalized to Kv7.1 full-length band intensity. Statistics were tested with one-way-ANOVA followed by Bonferroni’s Multiple
Comparison test. b Lysates derived from HeLa cells expressing Kv7.1-MYC and Kv7.1-D459A-MYC constructs treated with 1 µmol per L staurosporine for
8 h analyzed by immunoblotting. Untransfected (Ø) and vehicle-treated cells served as negative controls. Densitometric analysis of eight independent
experiments of the CTF2 band intensity normalized to Kv7.1 full-length band intensity. cWestern blot analysis of HeLa cell lysates overexpressing CT-MYC
construct treated for 8 h with 1 µmol per L staurosporine. Vehicle-treated cells served as negative controls. a−c Anti-MYC antibody, a, c anti-β-actin
antibody. All dot blots are shown as mean and error bars as SEM
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activation and cleavage. Next, we asked whether the generation of
the CTF2 was dependent on the full-length Kv7.1 α-subunit. We
therefore expressed the CT construct (Supplementary Fig. 1A)
under control and apoptotic conditions. Again, an increase in
CTF2 generation could be observed upon staurosporine treat-
ment (Fig. 2c) indicating that cleavage can occur independent
from the membrane-embedded part of the Kv7.1 protein. To gain
deeper insight into the involvement of caspases in Kv7.1 pro-
teolysis, we applied staurosporine and the speciﬁc caspase 8
inhibitor II to cells expressing Kv7.1. As shown in Fig. 3a, inhi-
bition of caspase 8 efﬁciently blocked activation of downstream
caspase 3 and the generation of CTF2 dose-dependently,
demonstrating that the staurosporine-induced CTF2 generation is
mediated by caspases.
To address the question whether caspase 3, one of the major
effector caspases, is solely responsible for Kv7.1 cleavage at
position D459, we used a human breast carcinoma MCF-7 cell
line, which is deﬁcient for caspase 3 37. Overexpression of Kv7.1
in MCF-7 cells still resulted in the generation of CTF2 albeit to a
lower extent (Fig. 3b, eGFP labeled lane). Whereas cotransfection
of Kv7.1 together with wild-type caspase-3 restored CTF2
production, the overexpression of an inactive form of caspase-3
led to a reduction of CTF2 levels (Fig. 3b) likely by protecting
Kv7.1 from endogenous caspases. To determine whether all
caspases cleave Kv7.1 to the same extent, we coexpressed Kv7.1
with at least one caspase of each group, namely caspases 1, 2, 3, 7,
and 8. Immunoblots revealed that all tested caspases are able to
generate CTF2 (Fig. 3c). Stronger cleavage could be observed by
overexpression of the initiator caspase 1, 2 and 8, which might be
due to an activation of downstream effector caspases. Never-
theless, these data suggest that Kv7.1 is a substrate of all analyzed
caspases.
To demonstrate that endogenous Kv7.1, embedded in the IKs
channel complex undergoes caspase-mediated proteolysis, we
treated murine cardiac muscle cells (HL-1 cells38) with increasing
concentrations of staurosporine, conﬁrming a dose-dependent
occurrence of CTF2 (Fig. 3d). Notably, full-length Kv7.1 channel
was efﬁciently cleaved at higher staurosporine concentrations. In
summary, our data strongly suggest that Kv7.1 is cleaved by
caspases at an aspartate at position 459.
Functional impact of proteolysis on Kv7.1/KCNE1 channels. To
analyze the functional impact of caspase-mediated cleavage of
Kv7.1 upon induction of apoptosis, we cotransfected HEK
293T cells with wild-type Kv7.1 and the D459A mutant together
with KCNE1 and measured whole-cell currents under staur-
osporine treatment and control conditions (Fig. 4a). Drug treat-
ment produced a small but signiﬁcant reduction of Kv7.1/KCNE1
currents, whereas currents generated by Kv7.1 D459A/KCNE1
channels remained unaffected (Fig. 4b). Cells were harvested after
patch-clamp measurements and were subjected to immunoblot
analysis to probe for CTF2. Again, we were able to detect CTF2 in
cells expressing wild-type Kv7.1 but not the D459A mutant
(Supplementary Fig. 3B). One possible explanation for the small
functional effect of caspase-mediated cleavage on Kv7.1/KCNE1-
mediated currents could be a protective effect of KCNE1 on Kv7.1.
Since the majority of our analysis so far was done using cells
expressing homomeric Kv7.1 channels, we therefore compared the
generation of CTF2 in presence and absence of KCNE1. As shown
in Fig. 4c, Kv7.1 is efﬁciently cleaved upon caspase activation even
in the presence of KCNE1 indicating that the β-subunit is not
shielding the heteromeric Kv7.1/KCNE1 complex from proteo-
lysis. Subsequently, we performed surface biotinylation experi-
ments to prove that the Kv7.1/KCNE1 heteromeric channels can
be processed at the plasma membrane by caspases as
demonstrated by the presence of CTF2 in the isolated fraction of
cell surface proteins (Fig. 4d). Furthermore, these data suggest that
CTF2 is, under this condition, still associated with the apoprotein
complex. In summary, these data strongly suggest that the activity
of heteromeric Kv7.1/KCNE1 channels can be modiﬁed by
caspase-mediated cleavage in the C-terminus of Kv7.1.
Identifying long-QT mutations modulating Kv7.1 proteolysis.
Next, we tested if disease-causing mutations in Kv7.1 can interfere
with the generation of CTF2 and focused on the LQT1 mutation
G460S, which is located just one amino acid downstream of the
aspartate residue important for Kv7.1 proteolysis (Fig. 4d).
Immunoblot analysis of the G460S mutant protein demonstrated
signiﬁcantly increased CTF2 levels when compared to wild-type
Kv7.1, indicating that this LQT1 mutation renders Kv7.1 more
susceptible to caspase-mediated cleavage even under non-
staurosporine treatment conditions (Fig. 4d). This observation is
in line with the ﬁnding that this mutation causes a decrease in
IKs-like currents39.
The caspase cleavage site resides in an approximately 80 amino
acid-long intervening loop between helices A and B (Fig. 4d).
Both helices contain an IQ motif, which is important for
calmodulin binding (Fig. 4d). Recently, it has been suggested by
crystallography, molecular modeling, biochemical, and functional
analyses that one bifunctional calmodulin molecule embraces
both helices from one Kv7.1 subunit34. Given the important role
of calmodulin for Kv7.1 function, we asked whether LQT1-
associated mutations within the calmodulin binding sites interfere
with CTF2 generation. Indeed, the analyses of the Kv7.1 A372D
mutation, which is located close to the calmodulin binding motif
in helix A, revealed no detectable CTF2 in immunoblots (Fig. 4d).
Coimmunoprecipitations proved that the A372D mutation
impaired the interaction of endogenous calmodulin with Kv7.1
(Fig. 4e), suggesting that calmodulin binding is necessary for
caspase-mediated proteolysis of Kv7.1.
Doxorubicin induces Kv7.1 proteolysis in cardiomyocytes. It is
well known that cancer treatment by the common antineoplastic
doxorubicin is hindered by severe cardiotoxic side effects, and
there is strong evidence in the literature that doxorubicin leads to
caspase activation in cardiomyocytes40. In order to determine
whether interference with cardiac function by doxorubicin also
involves caspase-mediated cleavage of Kv7.1, we treated human-
induced pluripotent stem cell-derived cardiomyocytes with
staurosporine and doxorubicin. In total lysates derived from
untreated human-induced pluripotent stem cell-derived cardio-
myocytes, we could only detect trace amounts of CTF2, when we
used the C-terminal Kv7.1 antibody to precipitate Kv7.1 (compare
Fig. 5a and Supplementary Fig. 3C). We were also unable to
detect CTF2 in murine cardiomyocytes (Fig. 3d) and tissue
(Supplementary Fig. 1B), suggesting that baseline levels of CTF2
and likely Kv7.1 proteolysis are rather low. However, staur-
osporine and doxorubicin activated caspase 3 as indicated by the
occurrence of cleaved-active forms and a reduction of the inactive
zymogen of the protease (Fig. 5a). Doxorubicin treatment at
higher concentration appeared to be more efﬁcient in producing
active caspase 3, which correlated with a higher abundance of
CTF2 and a strong reduction of monomeric and tetrameric forms
of Kv7.1 (Fig. 5a). Interestingly, we detected a potentially dimeric
form of Kv7.1 at 150 kDa in staurosporine- and doxorubicin-
treated cells, suggesting that the caspase-mediated destruction of
tetramers results in Kv.7.1 dimers in human-induced pluripotent
stem cell-derived cardiomyocytes (Fig. 5a). Nevertheless, lower
doses of doxorubicin failed to produce similar levels of CTF2,
which correlated with a decrease in caspase 3 activation (Fig. 5b).
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Fig. 3 Caspases are responsible for the generation of CTF2. a Western blot analysis of lysates derived from HEK 293T cells stably expressing
Kv7.1-MYC treated with either 1 µmol per L staurosporine for 6 h or treated with 1 µmol per L staurosporine for 6 h and pretreated for 2 h with 20 or
50 µmol per L of a caspase-8 inhibitor II. Untransfected (Ø) and vehicle-treated cells served as negative controls. Densitometric analysis of 4–6
independent experiments of the CTF2 band intensity normalized to Kv7.1 full-length band intensity. Statistics were tested with one-way-ANOVA
followed by Bonferroni’s Multiple Comparison test. # indicates nonspeciﬁc binding of the antibody. b MCF-7 lysates expressing Kv7.1-MYC and
caspase-3 or caspase-3-D28A-D175A analyzed by immunoblot. Untransfected (Ø) and eGFP-transfected cells served as negative controls. # indicates
nonspeciﬁc binding of the antibody. c Lysates of HEK 293T cells stably expressing Kv7.1 and coexpressing indicated caspases analyzed by immunoblot.
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Multiple Comparison test. a−c Anti-MYC antibody. Anti-β-actin antibody. a, b, d Anti-caspase-3 antibody. d Anti-Kv7.1 antibody. All dot blots are
shown as mean and error bars as SEM
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Discussion
To date, over 1500 caspase cleavage sites and substrates have been
identiﬁed41. The vast majority of caspase-mediated cleavage
occurs during apoptosis, but caspase function has also been
demonstrated in nonapoptotic cellular responses42, suggesting
that caspases cleave a speciﬁc subset of substrates independent of
apoptosis. Here, we report Kv7.1 as a novel substrate for caspases,
representing to our knowledge the ﬁrst example of a voltage-gated
cation channel undergoing caspase-mediated proteolysis. How-
ever, the transient receptor potential melastin-like 7 (TRMP7) has
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been also identiﬁed as a caspase substrate, which appears to be
critical for Fas-induced apoptosis43.
Cleavage of human Kv7.1 by caspases occurs after an aspartate
at position 459, which is located within the intervening loop
between helices A and B in the channel’s large cytoplasmic
C-terminal domain that serves as a scaffold for numerous protein
−protein interactions involved in cellular signaling cascades15.
Both helices appear to form a two-helical bundle, which is
embraced by a calmodulin molecule as revealed by X-ray crys-
tallography of recombinantly expressed calmodulin and the
proximal C-terminus of Kv7.134. In this study, the intervening
loop, in which the caspase-mediated proteolysis of Kv7.1 occurs,
was deleted. Thus, structural information about the caspase
cleavage site is missing so far. However, our ﬁnding that the
calmodulin binding-deﬁcient Kv7.1 A372D mutant is not pro-
cessed by caspases strongly suggest that calmodulin either helps
to recruit caspases to the channel complex or determines the
structure of the intervening loop necessary for proper caspase
recognition.
Our functional analysis using patch-clamp suggests that cas-
pase cleavage interferes with the function of Kv7.1. This ﬁnding is
supported by numerous reports showing that the intracellular
C-terminal domain of Kv7.1 is responsible for channel tetra-
merization, trafﬁcking and modulating the biophysical properties
of the channel15. The rather small effect of Kv7.1 cleavage on
whole-cell currents could be explained by the continued asso-
ciation of CTF2 with the apoprotein complex. For example, cal-
modulin could, by binding to helices A and B, act as a bridging
molecule. Alternatively, the interaction of CTF2 via helices C and
D with uncleaved Kv7.1 subunits could keep CTF2 in the channel
complex. However, our cell surface biotinylation data strongly
suggest that CTF2 is still present in heteromeric Kv7.1/KCNE1
localized at the plasmalemma.
Many pathogenic LQT1 mutations have been mapped to the
C-terminus of Kv7.1 emphasizing the functional importance of
this particular channel region44. Our ﬁnding that the LQT1
mutation G460S, which is adjacent to the aspartate 459 residue, is
more susceptible to caspase cleavage suggest a potential novel
pathophysiologic mechanism for LQT1 mutations located in the
C-terminus of Kv7.1.
Based on the analysis of a number of cleavage sites, a general
consensus motif of DXED-A/G/S/T has been proposed for
apoptosis executioner caspases such as caspases 3 and 7, whereas
caspases 2, 8, 9, and 10 and caspases 1, 4, 5, 6, and 14, prefer
isoleucine/ leucine or tryptophan/tyrosine/valine instead of an
aspartate at the ﬁrst position, respectively41. Due to the over-
lapping speciﬁcity of caspases and the signiﬁcantly different Kv7.1
cleavage site (amino acid sequence: FSVD-G), it is difﬁcult to
predict which individual caspase cleaves Kv7.1. Our coexpression
data suggest that Kv7.1 can be cleaved by all tested caspases
including caspases 1, 2, 3, 7 and 8. In this group, caspase 1 was
more efﬁcient in Kv7.1 processing, which is in agreement with the
larger similarity of the preferred cleavage site41.
Caspases have well-established functions in the execution of
apoptosis, as well as inﬂammation28. However, transiently active
caspases have also been detected in nonapoptotic cells. For
example, in neurons, caspases 3 and 9 are critical for long-term
depression and AMPA receptor internalization32. In the heart,
increased expression of caspase 1 was found in murine heart
failure models and in patients with end-stage heart failure31.
Analysis of mice with heart-targeted overexpression of caspases 1
and 3 further supported the notion that caspases contribute to
heart diseases, likely based on an overlap of apoptotic and non-
apoptotic functions30,31. Our ﬁnding that IKs is sensitive to
caspase-mediated cleavage uncovers a novel molecular mechan-
ism that may contribute to cardiac arrhythmias, which is strongly
supported by an increased susceptibility of the LQT1 G460S
mutant to proteolytic processing by caspases. Thus, it is likely that
the reported 40% smaller current density of the G460S mutant,
when compared to wild-type IKs, is at least partially due to an
increased cleavage of the mutant39. Although several C-terminally
located LQT1 mutations have been identiﬁed which interfere with
channel function by modulating calmodulin16,45 or phosphati-
dylinositol 4,5-bisphosphate46 binding and/or disrupt assembly of
functional IKs15, for most of the C-terminal LQT mutations, the
pathophysiological mechanism that leads to disease is unknown.
Our data strongly suggest that susceptibility to caspase-mediated
degradation should also be considered when analyzing these
mutations.
Furthermore, our results demonstrate that doxorubicin treat-
ment of human-induced pluripotent stem cell-derived cardio-
myocytes efﬁciently induced caspase-mediated cleavage of Kv7.1,
suggesting that this pathway might contribute to doxorubicin-
induced cardiotoxicity. Interestingly, doxorubicin has also been
shown to induce electrocardiogram abnormalities such as QT
interval prolongations, which are often observed within the ﬁrst
day after chemotherapy25. These results have been conﬁrmed in
animal studies, showing that doxorubicin prolongs the cardiac
action potential duration by speciﬁcally inactivating IKs but not
IKr, which both compose the delayed rectiﬁer potassium current
IK23. In cardiomyocytes, IKs is mediated by a macromolecular
complex formed by assembly of the pore-forming subunits Kv7.1
with KCNE1 β-subunits, which are linked to the scaffolding
protein yotiao/A-kinase anchoring protein 9 (AKAP-9)20. Yotiao
binds to the distal part of the C-terminus of Kv7.1 and recruits
PKA, protein phosphatase 1 (PP1), adenylate cyclase 9 (AC9) and
phosphodiesterase PDE4D3 to the complex, allowing the control
of the phosphorylation state of Kv7.1, which is the molecular basis
Fig. 4 Cleavage of Kv7.1 in physiology and pathophysiology. a Representative current traces for Kv7.1-MYC and Kv7.1-D459A-MYC, both coexpressed with
KCNE1. b Mean currents amplitude was plotted versus voltage to obtain current−voltage (I−V) relationships in cells expressing Kv7.1-MYC (n= 39
for vehicle, n= 16 for staurosporine treatment) or Kv7.1-D459A-MYC (n= 27 for vehicle, n= 17 for staurosporine treatment) and KCNE1 treated with
500 nmol per L staurosporine for 10–12 h. Statistics were tested with two-way ANOVA followed by Bonferroni post-tests. c Immunoblot analysis of HeLa
cells coexpressing Kv7.1 with KCNE1-MYC treated with 1 µM staurosporine for 4.5 h. Untransfected (Ø) and vehicle-treated cells served as negative
controls. d Biotinylating study analyzed by immunoblots of Hek 293 cells coexpressing Kv7.1 and KCNE1-MYC treated with 1 µM staurosporine for 3 h.
Untransfected (Ø) cells as well as cells not treated with biotin served as negative controls. IP Immunoprecipitation. TL total lysate. e Schematic illustration
to highlight the position of G460 and A372 and calmodulin binding site in helix A. Western blot analysis of HeLa cell lysates overexpressing indicated
constructs. Untransfected (Ø) and Kv7.1-D459A-transfected cells served as negative controls. Densitometric analysis of four independent experiments of
CTF2 band intensity normalized to Kv7.1 full-length band intensity. Statistics were tested with one-way-ANOVA followed by Bonferroni’s Multiple
Comparison test. f Coimmunoprecipitation study analyzed by immunoblots of HeLa cells overexpressing wild-type Kv7.1 and the A372D mutant with
endogenous calmodulin. IP Immunoprecipitation with anti-Kv7.1 antibody, IB Immunoblot, TL total lysate. Untransfected cells (Ø) served as negative
control. c Anti-KCNE1 antibody, anti-caspase 3 antibody. c, d Anti-Kv7.1 antibody, anti-GAPDH antibody. e Anti-β-actin antibody. e, f Anti-MYC antibody.
f Anti-calmodulin antibody. All graphs are shown as mean and error bars as SEM
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for the β-adrenergic regulation of IKs20,47. In silico sequence
analyses of yotiao predict several potential caspase cleavage sites,
suggesting that this scaffold protein is also processed by cas-
pases41. Thus, it is conceivable that caspase-mediated processing
of Kv7.1 and likely yotiao contributes to the prolongation of the
QT interval mediated by doxorubicin. It will be important to
determine the pathway by which doxorubicin treatment leads to
elevated caspase activity and Kv7.1 cleavage. While it is widely
accepted that doxorubicin-induced cardiotoxicity is due to the
induction of mitochondrial dysfunction, resulting in an increased
production of ROS in the cytoplasm and consequent activation of
extrinsic and intrinsic apoptotic pathways, a more direct effect on
ROS-mediated signaling by the oxidizing activity of doxorubicin
on Fe2+ ions, as suggested by the alleviating effect of dexrazox-
ane, must also be considered. This will also clarify the issue of
whether regulated C-terminal cleavage of Kv7.1 is more generally
involved in ROS-mediated cardiac responses.
In summary, the present study demonstrates caspase-mediated
proteolysis of Kv7.1. Posttranslational modiﬁcations such as
phosphorylation, ubiquitination, sumoylation, palmitoylation,
and glycosylation have been reported for potassium channels48.
According to our data, proteolysis of Kv7.1 mediated by caspases
is another important mechanism of posttranslational modiﬁca-
tion of Kv7.1, and we hypothesize that analysis of this regulation
will advance understanding of the molecular mechanism of
doxorubicin-induced cardiotoxicity.
Methods
Plasmids and antibodies. Human Kv7.1 and caspase cDNAs were subcloned in
the expression vectors pFrog and pcDNA4/TO (Invitrogen, Waltham, USA),
respectively. Mutations, deletions and tags for antibodies were constructed/intro-
duced by recombinant PCR and veriﬁed by sequencing. The C-terminal anti-Kv7.1
antibody was directed against the following peptide sequence TVPRRGPDEGS.
The following antibodies were used: rabbit anti-β-actin (A2066, Sigma-Aldrich, St.
Louis, USA), rabbit anti-caspase 3 (8G10, Cell Signaling, Cambridge, UK), rabbit
anti-calmodulin (ab45689, Abcam, Cambridge, UK), rabbit anti-Eef2 (eukaryotic
translation elongation factor 2, ab33523, Abcam, Cambridge, UK), mouse anti-
GAPDH (MAB374, Millipore, Billerica, USA), rabbit anti-KCNE1 (APC-163,
Alomone Labs, Jerusalem, Israel), rabbit anti-Kv7.1 (ab77701, Abcam, Cambridge,
UK), mouse anti-MYC (9B11, Cell Signaling, Cambridge, UK), goat anti-MYC
(GTX29106, GeneTex Inc., Irvine, USA).
Cell culture, transfection, and inhibitors. HEK 293T, HeLa, Cos7, and MCF-7
(ATCC, Manassas, USA) were grown in Dulbecco’s modiﬁed Eagle’s medium
(DMEM, Thermo Fisher Scientiﬁc) supplemented with 10% fetal bovine serum
(FBS, Biochrome, Berlin, Germany), 100 U per mL penicillin and 100 µg per mL
streptomycin (both Carl Roth, Karlsruhe, Germany). For HL-1 cells (gift from
W.C. Claycomb), Claycomb medium (Sigma-Aldrich), supplemented with 10%
FBS (Biochrome), 100 U per mL penicillin, 100 µg per mL streptomycin, 0.1 mM
norepinephrine (Carl Roth) and 2 mM L-Glutamine (Carl Roth) was used. All cells
were kept at 37 °C and 5% CO2. Transient transfections were performed using
TurboFect (Thermo Fischer Scientiﬁc) according to the manufacturer’s instruc-
tions, and stable cell lines were established using G418 for selection. Inhibitors were
used as follows: Z-VAD-FMK (12 h, 100 µM, Promega, Fitchberg, USA), Q-VD-
OPh (12 h, 450 nM, Merck Millipore, Billerica, USA), staurosporine (1 to 8 h,
0.5–2 µM, Sigma-Aldrich), caspase-8 inhibitor II (2 h pretreatment, 20 or 50 µM,
Calbiochem, Billerica, USA), Doxorubicin (overnight, 0.1 µM–10 µM, Sigma-
Aldrich).
Protein extraction, immunoprecipitation, and immunoblotting. Cells were
washed twice with phosphate-buffered saline (PBS) and harvested in PBS, con-
taining a protease inhibitor cocktail (Complete, Roche, Basel, Switzerland). After
centrifugation, cell pellets were lysed in PBS/Complete (1% Triton X-100, Carl
Roth) by sonication. After 1 h incubation on ice, samples were centrifuged, and
supernatants were analyzed by SDS-PAGE. For coimmunoprecipitations and
immunoprecipitations, cells were lysed in EBC buffer/Complete (120 mM NaCl,
50 mM Tris-HCl, 0.5% NP-40, pH 7.4 (all from Carl Roth)) and treated as
described above. Lysates were incubated with mouse anti-MYC antibody (coim-
munoprecipitation) or treated with Kv7.1-myc antibody (immunoprecipitation) at
4 °C overnight. For precipitation, protein G agarose beads (coimmunoprecipita-
tion) or protein G dynabeads (immunoprecipitation) were used. After thorough
washing of the beads, protein complexes were released by denaturation. Samples
were subjected to SDS-PAGE and transferred onto nitrocellulose membranes by
tank blotting. Membranes were blocked and incubated overnight at 4 °C in primary
antibody solution followed by incubation with the appropriate secondary anti-
bodies conjugated to horseradish peroxidase. After thorough washing, bound
antibodies were detected by chemiluminescence using a luminescent imager
(LAS-4000, Fujiﬁlm, GE Healthcare, Little Chalfont, UK). For quantiﬁcations,
ImageJ software was used.
Biotinylating assay. After washing cells twice with PBS/CM (0.1 mM CaCl2, 1 mM
MgCl2), cells were incubated with 0.5 mg NHS biotin ester (Thermo Fisher) in
PBS/CM for 10 min. By adding 50 mM Glycin in PBS/CM biotinylation was
stopped. After two washing steps with PBS/CM, cells were lysed as described for
immunoprecipitation studies above. Incubation with Streptavidin beads for 1 h at 4
°C was used to precipitate biotinylated proteins. After through washing proteins
were released by denaturation and subjected to SDS-PAGE and immunoblotting as
described above.
Isolation of neonatal rat ventricular cardiomyocytes. Hearts of 1–2-day-old
Wistar rats were harvested and minced in buffer (120 mmol NaCl, 20 mmol
HEPES, 8 mmol NaH2PO4, 6 mmol glucose, 5 mmol KCl, 0.8 mmol MgSO4,
pH= 7.4). Subsequently, up to six digestion steps were carried out with 0.6 mg per
mL pancreatin (Sigma-Aldrich) and 0.5 mg per mL collagenase type II (Wor-
thington, Lakewood, USA) in sterile ADS buffer. Cardiomyocytes were puriﬁed
from contaminating ﬁbroblasts using a Percoll gradient centrifugation step. Finally,
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Fig. 5 Doxorubicin induces cleavage of Kv7.1 to CTF2. a Immunoblot
analysis of human-induced pluripotent stem cell-derived cardiomyocytes
treated either with vehicle, staurosporine (2 µM) for 4 h or doxorubicin
(10 µM) overnight. # indicates nonspeciﬁc binding of the Kv7.1 antibody.
b Densitometric analysis of 3–6 independent experiments of band
intensities of CTF2 normalized to GAPDH band intensity. Statistics were
tested with one-way-ANOVA followed by Bonferroni’s Multiple
Comparison test. a Anti-Kv7.1 antibody, anti-caspase-3 antibody, anti-
GAPDH antibody. All dot blots are shown as mean and error bars as SEM
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NRVMs were resuspended and cultured in DMEM containing 10% FBS, 100 U per
mL penicillin, 100 µg per mL streptomycin and 1% L-Glutamine. Protein extrac-
tions were performed as described above.
Human-induced pluripotent stem cell culture. Human-induced pluripotent stem
cell-derived cardiomyocytes49 were routinely maintained in E8 medium imple-
mented with 10 μM Rho kinase inhibitor (Y27632; Biorbyt, Cambridge, UK) for the
ﬁrst 24 h after passage on 1:400 reduced growth factor Matrigel (Corning, Corning,
USA). Cells were passaged ~1:15 every 3–4 days using 0.5 mM EDTA in Dulbecco’s
PBS (DPBS; Corning, Corning, USA) after achieving ~80% conﬂuence. Cell lines
were used between passages 20 and 85. All cultures were routinely tested for
mycoplasma using a MycoAlert PLUS Kit (Lonza, Basel, Switzerland).
Cardiac differentiation from human iPS cells. Cardiac differentiation was per-
formed as described previously49. Brieﬂy, to initiate differentiation, medium was
changed to CDM3, consisting of RPMI 1640 (Corning), 500 μg ml–1 Oryza sativa-
derived recombinant human albumin (Oryzogen, Wuhan, China), and 213 μg ml–1
L–ascorbic acid 2-phosphate (Wako, Tokyo, Japan). For days 0–1, media was
supplemented with 3 μM of the glycogen synthase kinase 3β inhibitor CHIR99021
(Biorbyt, San Francisco, USA)21,22 and 10 ng ml–1 BMP4 (Peprotech, Hamburg,
Germany). On day 1, media was changed to CDM3 and on d2 media was changed
to CDM3 supplemented with 2 μM of the Wnt inhibitor Wnt-C59 (Biorbyt). Media
was changed on day 4 and every other day thereafter with CDM3. Contracting cells
were noted from day 7. At days 25–29, contracting cardiomyocytes were dis-
sociated by incubating 20 min in DPBS followed by 6 min in TrypLE (Thermo
Fisher Scientiﬁc), and then 60 min with 0.5 U per mL Liberase TH (Roche) in
CDM3 media. Cells were replated in 40% FBS in CDM3 by combining 2–3 wells
into one well for optimal viability of the cultures. After 2 days, media was changed
back to CDM3 and exchanged every 2 days until analysis.
Electrophysiology. Transfected cells were identiﬁed by using cotransfection of
eGFP and imaging on an inverted ﬂuorescence microscope (Axiovert 40, Zeiss,
Jena, Germany) with a ﬁber optic-coupled light source (UVICO, Rapp OptoElec-
tronic, Hamburg, Germany). Current signals were recorded in whole-cell patch-
clamp mode at room temperature (22 ± 1 °C) 2 days after transfection. Recordings
were started 3 min after whole-cell access was obtained. Data were sampled at
20 kHz and ﬁltered at 5 kHz, using an Axopatch 200B ampliﬁer in combination
with a Digidata 1322A interface and pClamp10 software (all from Molecular
Devices/MDS Analytical Technologies, Sunnyvale, USA). Electrodes were made
from borosilicate glass (Harvard Apparatus, Edenbridge, UK or BioMedical
Instruments, Zoellnitz, Germany), using a DMZ-Universal Puller (Zeitz, Munich,
Germany). Pipette resistance in bath solution was 2.0–3.5 MΩ and access resistance
was typically <5MΩ before series resistance compensation (75%). External solution
contained (in mM): 145 NaCl, 4 KCl, 2 CaCl2, 2 MgCl2, 10 D-glucose, 10 HEPES,
adjusted to pH 7.4 with NaOH. The internal solution was composed of (in mM)
135 K-gluconate, 4 NaCl, 10 KCl, 5 Hepes, 5 EGTA, 2 Na2-ATP, 0.3 Na3-GTP
(pH 7.25 with KOH). Cells were incubated with staurosporine at a concentration of
500 nM 10–12 h before recordings. Chemicals were purchased from Sigma-Aldrich.
Statistics. Data are shown as means ± SEM of n observations, as indicated. Sta-
tistical analyses were performed using unpaired two-tailed Student’s t test, one-way
ANOVA and Bonferroni’s Multiple Comparison post hoc test or two-way ANOVA
followed by Bonferroni post-tests, where applicable, using the GraphPad
Prism 5 software (GraphPad, San Diego, USA). p ≤ 0.05 was termed signiﬁcant.
*0.01 ≤ p ≤ 0.05. **0.001 ≤ p < 0.01. ***p < 0.001.
Data availability
The authors declare that the data supporting the ﬁndings of this study are available
within the paper and its supplementary information ﬁles.
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